Aerie Pharmaceuticals Stock Forecast, Price & News

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

Is Aerie Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aerie Pharmaceuticals stock.
View analyst ratings for Aerie Pharmaceuticals or view top-rated stocks.

How has Aerie Pharmaceuticals' stock price been impacted by COVID-19?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AERI shares have decreased by 33.7% and is now trading at $9.65.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aerie Pharmaceuticals?

Aerie Pharmaceuticals saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 4,270,000 shares, a decrease of 26.4% from the October 31st total of 5,800,000 shares. Based on an average daily trading volume, of 812,900 shares, the short-interest ratio is presently 5.3 days. Approximately 9.4% of the company's shares are sold short.
View Aerie Pharmaceuticals' Short Interest.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Aerie Pharmaceuticals.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. The company had revenue of $29.31 million for the quarter, compared to analyst estimates of $29.13 million. Aerie Pharmaceuticals had a negative trailing twelve-month return on equity of 1,531.00% and a negative net margin of 159.85%. During the same period in the prior year, the firm earned ($0.65) EPS.
View Aerie Pharmaceuticals' earnings history.

What price target have analysts set for AERI?

4 analysts have issued twelve-month price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $15.65 to $29.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $23.66 in the next twelve months. This suggests a possible upside of 145.2% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:

• Thomas A. Mitro, President & Chief Operating Officer
• Casey C. Kopczynski, Chief Scientific Officer
• Richard Lewis, Chief Medical Officer
• Luis G. Vargas, Medical Director
• David A. Hollander, Chief Research & Development Officer

Who are some of Aerie Pharmaceuticals' key competitors?

Some companies that are related to Aerie Pharmaceuticals include Krystal Biotech (KRYS), Inhibrx (INBX), Atara Biotherapeutics (ATRA), Immunocore (IMCR), REGENXBIO (RGNX), Coherus BioSciences (CHRS), Replimune Group (REPL), AlloVir (ALVR), Sangamo Therapeutics (SGMO), iTeos Therapeutics (ITOS), Rubius Therapeutics (RUBY), Ocugen (OCGN), Vaxcyte (PCVX), Caribou Biosciences (CRBU) and Humacyte (HUMA).
View all of AERI's competitors.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (6.08%), Granahan Investment Management Inc. MA (2.94%), Schroder Investment Management Group (2.81%), Citigroup Inc. (2.65%), Rice Hall James & Associates LLC (2.61%) and Pinnacle Associates Ltd. (1.46%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski and Gerald D Cagle.
View institutional ownership trends for Aerie Pharmaceuticals.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Integral Health Asset Management LLC, Geode Capital Management LLC, Millennium Management LLC, Schroder Investment Management Group, Voloridge Investment Management LLC, Two Sigma Advisers LP, and Renaissance Technologies LLC.
View insider buying and selling activity for Aerie Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Granite Investment Partners LLC, Tudor Investment Corp Et Al, Jacob Asset Management of New York LLC, Citadel Advisors LLC, Martingale Asset Management L P, Endurance Wealth Management Inc., and Thompson Investment Management Inc..
View insider buying and selling activity for Aerie Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $9.65.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals has a market capitalization of $457.00 million and generates $83.14 million in revenue each year. The company earns $-183.10 million in net income (profit) each year or ($3.61) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

Aerie Pharmaceuticals employs 365 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Where are Aerie Pharmaceuticals' headquarters?

Aerie Pharmaceuticals is headquartered at 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at (919) 237-5300, via email at [email protected], or via fax at 949-526-8787.